EUVIMEDEUVIMED entdecken
Crossref

Assessment of Treatment Response in Patients Diagnosed with Waldenström’s Macroglobulinemia: Single-Center Experience

Şeyma Yavuz, Vildan Ozkocaman, Vildan Gürsoy, Tuba Ersal, İbrahim Ethem Pınar, Fazıl Cagrı Hunutlu, Ezel Elgun, Fahir Özkalemkaş

Uludağ Üniversitesi Tıp Fakültesi Dergisi · 24.08.2026 · 52

DOI: 10.32708/uutfd.1954370 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Uludağ Üniversitesi Tıp Fakültesi Dergisi, online erschienen am 24.08.2026. Verfasst von Şeyma Yavuz und 7 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Waldenström macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma characterized by the production of monoclonal IgM. It may lead to symptoms such as hyperviscosity syndrome, anemia, and neuropathy. The indication for treatment is not based on a specific IgM level but is determined according to the clinical condition. This study aimed to retrospectively evaluate the treatment responses of patients diagnosed with WM between 2019 and 2024 at the Hematology Outpatient Clinic, Department of Internal Medicine, X Hospital. A total of 29 patients were included. Demographic characteristics and first- and second-line treatment responses were analyzed. The median age at diagnosis was 78 years; 69% were male. The median follow-up duration was 58.76 months. According to the IPS risk score, 20.7% were low risk, 27.6% intermediate risk, and 51.7% high risk. Treatment was initiated in 82% of patients, with rituximab plus bendamustine (R-Benda) being the most frequently used regimen. The overall response rate to first-line therapy was 75.9%. Among laboratory parameters, hemoglobin, platelet count, and LDH were identified as predictive factors for mortality. No significant difference in survival was observed according to IPS risk score at diagnosis (p>0.05). Survival differences were assessed using Kaplan-Meier analysis. Patients who achieved a response to first-line therapy demonstrated longer survival. Conventional immunochemotherapy remains an effective and tolerable treatment option in WM. However, larger comparative studies with novel agents such as Bruton tyrosine kinase (BTK) inhibitors are needed. Treatment decisions in WM should be individualized based on patient characteristics and clinical findings.

Zitieren

APA

Yavuz, Ş., Ozkocaman, V., Gürsoy, V., Ersal, T., Pınar, İ. E., Hunutlu, F. C., Elgun, E., & Özkalemkaş, F. (2026). Assessment of Treatment Response in Patients Diagnosed with Waldenström’s Macroglobulinemia: Single-Center Experience. Uludağ Üniversitesi Tıp Fakültesi Dergisi, 52. https://doi.org/10.32708/uutfd.1954370

Vancouver

Yavuz Ş, Ozkocaman V, Gürsoy V, Ersal T, Pınar İE, Hunutlu FC, et al. Assessment of Treatment Response in Patients Diagnosed with Waldenström’s Macroglobulinemia: Single-Center Experience. Uludağ Üniversitesi Tıp Fakültesi Dergisi. 2026;52. doi:10.32708/uutfd.1954370

BibTeX
@article{Yavuz2026,
  author = {Yavuz, Şeyma and Ozkocaman, Vildan and Gürsoy, Vildan and Ersal, Tuba and Pınar, İbrahim Ethem and Hunutlu, Fazıl Cagrı and Elgun, Ezel and Özkalemkaş, Fahir},
  title = {Assessment of Treatment Response in Patients Diagnosed with Waldenström’s Macroglobulinemia: Single-Center Experience},
  journal = {Uludağ Üniversitesi Tıp Fakültesi Dergisi},
  year = {2026},
  volume = {52},
  doi = {10.32708/uutfd.1954370}
}
Kostenlos starten →